- Home
- LCTX vs FLL Comparison
LCTX vs FLL Comparison
Compare LCTX & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LCTX | FLL |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.7M | 77.7M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LCTX | FLL |
|---|---|---|
| Price | $1.14 | $2.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $6.25 | $4.00 |
| AVG Volume (30 Days) | ★ 795.4K | 116.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.45 |
| EPS | ★ N/A | N/A |
| Revenue | $14,556,000.00 | ★ $302,376,000.00 |
| Revenue This Year | $109.40 | $7.54 |
| Revenue Next Year | N/A | $6.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | 3.53 |
| 52 Week Low | $1.00 | $1.96 |
| 52 Week High | $2.09 | $3.61 |
Technical Indicators
Market Signals| Indicator | LCTX | FLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 43.89 |
| Support Level | $1.02 | $1.99 |
| Resistance Level | $1.18 | $2.74 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 38.62 | 33.33 |
Price Performance
Historical ComparisonAbout LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.